Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non‐small cell lung cancer

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein involved in the metabolism of low‐density lipoprotein cholesterol. However, the role of plasma PCSK9 in predicting the efficacy of ICIs in advanced non‐small cell lung cancer (NSCLC) remains to be clarified. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Mengqing, Yu, Xin, Chu, Xiangling, Xie, Huikang, Zhou, Juan, Zhao, Jing, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807327/
https://www.ncbi.nlm.nih.gov/pubmed/34962050
http://dx.doi.org/10.1111/1759-7714.14259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807327/
https://www.ncbi.nlm.nih.gov/pubmed/34962050
http://dx.doi.org/10.1111/1759-7714.14259

Ejemplares similares